
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics Inc. has exhibited strong revenue growth, with Q3'25 revenues reaching $27.3 million, reflecting a 63.3% year-over-year increase, significantly surpassing estimates. Management has revised upward its revenue projections for 2025 and 2026 to $97.5 million and $136 million, respectively, indicating confidence in sustained growth driven by robust new patient starts, particularly from the pharmacy channel. The company’s expansion into multiple daily injection patient conversions and the addition of sales territories further positions it for continued market penetration and higher-margin sales in the upcoming years.
Bears say
Beta Bionics Inc faces significant risks that could adversely impact its financial outlook, including challenges in gaining market share for its iLet product amidst competitive pressures and potential hurdles in expanding pharmacy channel access. The company's projected EBITDA loss of $12.2 million significantly exceeded earlier estimates, indicating financial strain and raising concerns about profitability. Additionally, the need for further capital may lead to shareholder dilution, compounded by uncertainties in Medicare reimbursement models and a slower-than-anticipated sales force ramp-up, which could hinder revenue growth moving forward.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares